Nalmefene Implant in Healthy Subjects

A Phase 1, Open-Label, Safety, Tolerability, and Pharmacokinetic Study of Nalmefene Implants in Healthy Subjects

The goal of this clinical trial is to learn how safe either one or two nalmefene implants are after remaining implanted for 4 or 12 weeks.

Additionally the pharmacokinetics (PK), how fast the drug is absorbed into the body and how long it remains in the body, will also be studies.

The data collected in this healthy volunteer study will inform the Sponsor on how best to proceed with future trials in the intended patient population.

Study Overview

• Status: Recruiting
• Conditions: Opioid Abuse and Addiction
• Intervention / Treatment: Drug: 1 Nalmefene implant; Drug: 2 Nalmefene implants

Detailed Description

This is a single center, Phase 1, open-label, safety, tolerability, and PK study designed to compare one (1) or two (2) nalmefene implants in healthy subjects.

The study will include a screening period from Day -28 to Day -2, where subjects will be evaluated according to the Inclusion/Exclusion Criteria. Enrollment will be initially restricted to Cohort 1 (1 implant) until the Safety Review Committee (SRC) completes an evaluation of the safety data, of at least 5 subjects, through the Week 4 Visit. The SRC will then advise the Sponsor as to whether to open enrollment to Cohort 2 (2 implants).

Including screening, the first 8 subjects will be enrolled into Cohort 1 Subgroup 1 and will be seen for 16 visits over a period of up to 18 weeks. This includes a total of up to 8 nights of inpatient stay during that period. Eligible subjects will be admitted to the clinical site on Day -1 and implant insertion will occur on Day 1. Subjects will be confined until completion of the assessments on Day 2. Subjects will return to the clinical site for outpatient visits on Days 3 and 4, and Weeks 1, 2, 3, 4, 6, 8, and 10. Subjects will be admitted again two days prior to the Week 12/End of Treatment for an implant removal visit and will be discharged after the final blood sample is collected 72 hours after implant removal. Subjects will return to the clinical site for follow-up visits on Week 13 and Week 14 (1 and 2 week(s) following implant removal procedure) for removal of sutures (if any) and safety evaluations.

Including screening, subjects enrolled into Cohort 1 Subgroup 2 and Cohort 2 will be seen for approximately 22 visits over a period of up to 30 weeks. This includes a total of 8 nights of inpatient stay during that period. Eligible subjects will be admitted to the clinical site on Day -1 and implant insertion will occur on Day 1. Subjects will be confined until completion of the assessments on Day 2. Subjects will return to the clinical site for outpatient visits on Days 3 and 4, and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22. Subjects will be admitted again on the day prior to the Week 24/EOT implant removal visit and will be discharged after the final blood sample is collected 72 hours after implant removal. Subjects will return to the clinical site for follow-up visits on Week 25 and Week 26 (1 and 2 week(s) following implant removal procedure) for removal of sutures (if any) and safety evaluations.

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Rajesh Patel, PhD; Phone Number: 1-833-824-0824; Email: rpatel@reacxpharma.com
• Study Contact Backup: Name: Susan Lee; Email: slee@reacxpharma.com

Study Locations

• United States
  • North Carolina
    • Morrisville, North Carolina, United States, 27560
      • Recruiting
      • Premier Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

- Subjects must meet all of the following criteria to be included in the study:

1. Male or female, non-smoker, ≥18 and ≤55 years of age, with body mass index (BMI) >18.5 and <35.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.

2. Healthy as defined by:

   1. the absence of clinically significant illness and surgery within 4 weeks prior to implant insertion.
   2. the absence of clinically significant history of dermatologic, neurological, musculoskeletal, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.

3. Female subjects of non-childbearing potential must be:

   1. post-menopausal with confirmation by documented follicle-stimulating hormone (FSH) test; or
   2. surgically sterile .
4. Female subjects of childbearing potential who are sexually active with a non-sterile male partner must be willing to use an acceptable contraceptive methods throughout the study and for 30 days after the implant is removed:
5. Male subjects who are not vasectomized for at least 3 months prior to implant insertion and who are sexually active with a female partner of childbearing potential must be willing to use an acceptable contraceptive methods from implant insertion and for 30 days after the implant is removed:

6 Able to understand the study procedures and provide signed informed consent to participate in the study.

Exclusion Criteria:

• Subjects to whom any of the following applies will be excluded from the study:

  1. Any clinically significant abnormal finding at physical examination at screening.
  2. Clinically significant history of or current evidence of suicidal ideation or active suicidal behavior as based on the C-SSRS.
  3. Clinically significant history or current evidence of depression as based on the MADRS.
  4. Clinically significant abnormal laboratory test results or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody at screening.
  5. Positive pregnancy test or lactating female subject.
  6. Positive urine drug screen, urine cotinine test, or alcohol breath test.
  7. Known medically significant intolerance or allergic reactions to nalmefene or to ethylene vinyl acetate
  8. Hypersensitivity to lidocaine or other local anesthetics of the amide type, epinephrine, antiseptic solution
  9. Clinically significant ECG abnormalities or vital signs abnormalities
  10. History of drug use within 1 year prior to screening or recreational use of marijuana within 1 month
  11. History of alcohol abuse within 1 year prior to screening

  12. Use of medications for the timeframes specified below:

      1. depot injection or implant within 3 months prior to implant insertion;
      2. any drug known to induce hepatic drug metabolism within 30 days prior to implant insertion;
      3. prescription medications within 14 days prior to implant insertion;
      4. any vaccine within 14 days prior to implant insertion;
      5. over-the-counter medications and natural health products within 7 days prior to implant insertion
  13. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to implant insertion,
  14. Donation of plasma within 7 days prior to dosing or donation or
  15. Intolerant to venipuncture and/or have difficulty with venous access.
  16. History of wound healing problems.
  17. Lymphedema, scarring, or tattoos on his/her inner upper arms within 2 months prior to screening or a history of keloid scarring.
  18. Any dermatologic disorder, including cancer, that precludes the safety of the implant
  19. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Cohort 1; 1 Implant	Drug: 1 Nalmefene implant; One implant
Active Comparator: Cohort 2; 2 Implants	Drug: 2 Nalmefene implants; Two Implants

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with Adverse Events (AEs) after implantation with 1 or 2 nalmefene implants.		Day 1 up to Week 12 or Week 24
Columbia-Suicide Severity Rating Scale (C-SSRS)	Questionnaire	Day 1 and Day 2
Montgomery-Asberg Depression Rating Scale (MADRS)	Questionnaire	Day 1 and Day 2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum observed plasma concentration (Cmax) of nalmefene after implantation with 1 or 2 nalmefene implants.	PK blood sample	Day 1, 2, 3, 4, Weeks 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18, 20, 22, 24, 25, 26
Area under the concentration curve (AUC) after implantation with 1 or 2 nalmefene implants	PK blood sample	Day 1, 2, 3, 4, Weeks 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18, 20, 22, 24, 25, 26
Plasma concertation of nalmefene after implantation with 1 or 2 nalmefene implants	PK blood sample	Day 1, 2, 3, 4, Weeks 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18, 20, 22, 24, 25, 26

Collaborators and Investigators

• Sponsor: ReacX Pharmaceuticals, Inc.
• Collaborators: National Institute on Drug Abuse (NIDA)

Study record dates

Study Major Dates

• Study Start (Actual): February 23, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: December 17, 2025
• First Submitted That Met QC Criteria: January 6, 2026
• First Posted (Actual): January 8, 2026

Study Record Updates

• Last Update Posted (Actual): April 6, 2026
• Last Update Submitted That Met QC Criteria: April 3, 2026
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: nalmefene implant opioid addition
• Additional Relevant MeSH Terms: Narcotic-Related Disorders; Mental Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Compulsive Behavior; Impulsive Behavior; Behavior; Opioid-Related Disorders; Behavior, Addictive
• Other Study ID Numbers: NI-001; 5UGDA047707-02 (Other Grant/Funding Number: NIDA)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No